# Diabetes Research Hub — Monitor Report
**Date:** 2026-03-29
**Automated scan by:** Cowork Scheduled Task (diabetes-hub-monitor)

---

## File System Status

| File | Last Modified | Status |
|------|--------------|--------|
| hub_monitor_report.md | 2026-03-29 02:04 | Fresh (today) |
| clinical_trials_latest.json | 2026-03-29 02:04 | Fresh (today) |
| pubmed_recent_latest.json | 2026-03-29 02:04 | Fresh (today) |
| literature_gap_data.json | 2026-03-15 00:45 | **STALE — 14 days old (at threshold)** |
| literature_gap_report.md | 2026-03-28 10:21 | Fresh (yesterday) |
| hub_monitor_state.json | 2026-03-29 02:04 | Fresh (today) |

**Hub monitor detected:** 488 total files tracked, 3 new files, 28 modified files, 0 removed. No issues flagged.

**New files since last scan:**
- clinical_trials_snapshot_2026-03-29.json (507.8 KB)
- monitor_report_2026-03-28.md (11.3 KB)
- pubmed_recent_snapshot_2026-03-29.json (96.2 KB)

---

## Clinical Trial Changes

### Snapshot Comparison (2026-03-28 → 2026-03-29)

**No changes detected:**
- New trials: 0
- Removed trials: 0
- Status changes: 0
- New results posted: 0

This is a quiet day for the trial portfolio. The previous day (March 28) saw 2 new trials and 2 status changes; today's snapshot is identical to yesterday's.

### Key Recruiting Phase 3 Trials (Priority Watch List — unchanged)

**Total recruiting Phase 3 trials:** 44 (stable)

**From key sponsors (all still RECRUITING):**

| NCT ID | Title | Sponsor | Category |
|--------|-------|---------|----------|
| NCT04786262 | VX-880 Safety, Tolerability, and Efficacy | **Vertex Pharmaceuticals** | T1D Cure (Cell Therapy) |
| NCT06832410 | VX-880 Efficacy, Safety, and Tolerability | **Vertex Pharmaceuticals** | T1D Cure (Cell Therapy) |
| NCT07222137 | Baricitinib for Delay of Stage 3 T1D | **Eli Lilly** | T1D Immunotherapy |
| NCT07222332 | Baricitinib to Preserve Beta Cell Function | **Eli Lilly** | T1D Immunotherapy |
| NCT06972472 | Orforglipron in Obesity/Overweight | **Eli Lilly** | T2D Novel Therapy |
| NCT06993792 | Orforglipron Master Protocol | **Eli Lilly** | T2D Novel Therapy |
| NCT07076199 | Insulin Icodec (weekly insulin) | **Novo Nordisk** | T2D Technology |
| NCT07271251 | Oral Semaglutide Formulations | **Novo Nordisk** | T2D Novel Therapy |
| NCT06739122 | Dulaglutide Pediatric Dosing | **Eli Lilly** | Youth Diabetes |

### Overall Trial Portfolio (756 total — stable)

| Category | Count |
|----------|-------|
| T1D Cure & Cell Therapy | 153 |
| T1D Immunotherapy & Prevention | 71 |
| T2D Novel Therapies (Phase 2-3) | 137 |
| Diabetes Technology (Devices) | 218 |
| Recently Completed with Results | 249 |

---

## PubMed Highlights

### Publication Volume (Last 30 Days) — 130 unique papers across 15 domains

**High Activity Domains:**

| Domain | Total Papers | Trend |
|--------|-------------|-------|
| Diabetes AI/ML | 212 | Dominant — sustained high volume |
| Diabetes Microbiome | 176 | Very high (↑ from 170 yesterday) |
| T2D GLP-1 New | 160 | Sustained high, driven by semaglutide/tirzepatide research |
| Diabetes Biomarker | 149 | Strong activity |
| Diabetes Health Equity | 79 | Significant and growing |

**Low Activity Domains (potential monitoring gaps):**

| Domain | Total Papers | Signal |
|--------|-------------|--------|
| LADA New Research | 8 | Persistently low — aligns with gap analysis |
| Diabetes Drug Repurpose | 7 | Under-explored (Tier 1 in Doctrine) |
| Diabetes Epigenetics | 5 | Very low |

### New Cross-Domain Papers (since yesterday — 2 found)

These are the highest-value papers identified by the hub_monitor diff:

| PMID | Title (abbreviated) | Domains | Significance |
|------|---------------------|---------|-------------|
| 41898821 | Gestational Diabetes and Genetics | Diabetes Epigenetics + Multi-Omics | Cross-omics approach to GDM — aligns with Tier 1 Multi-Omics Biomarker Integration |
| 41899527 | Systems-Level Transcriptomic Integration: T2D + HBV → Cholangiocarcinoma | Diabetes Biomarker + Drug Repurpose | Network pharmacology approach — aligns with Tier 1 Drug Repurposing |

### Continuing Priority Papers (from prior reports)

| PMID | Title (abbreviated) | Why It Matters |
|------|---------------------|----------------|
| 41872174 | Antigen-specific immunotherapy with CD4 T cells (Nature Communications) | T1D Stem Cell Cure + Immunotherapy; islet transplant tolerance without immunosuppression |
| 41893308 | Mechanistic Insights into T2D Remission (Metabolites) | T2D Remission + Microbiome + Multi-Omics — Tier 1 & 2 alignment |
| 41886504 | Whole-genome CRISPR screening for stem cell-derived islet transplant | Gene therapy approach to improving islet transplant outcomes |
| 41895502 | Clinically relevant lipid nanoparticle base editing in pancreas | Novel delivery method for pancreatic gene editing — preclinical |

### Key Therapy Mentions

No papers in the last 30 days specifically mentioned zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, or teplizumab in their PubMed-captured titles/abstracts. These therapies are tracked primarily through ClinicalTrials.gov.

---

## Gap Analysis Summary

**Data freshness:** Gap data is from 2026-03-15 — **now 14 days old, at the stale threshold.** Re-run recommended today.

### Top 5 Under-Researched Intersections (by Gap Score)

| Rank | Domain Pair | Gap Score | Joint Pubs | Tier 1 Alignment |
|------|------------|-----------|------------|------------------|
| 1 | Beta Cell Regen × Health Equity | 100.0 | 0 | Yes — Epidemiological Data Analysis |
| 2 | Insulin Resistance × Islet Transplant | 100.0 | 1 | Yes — Literature Synthesis |
| 3 | Islet Transplant × Drug Repurposing | 100.0 | 0 | Yes — Drug Repurposing Screening |
| 4 | Islet Transplant × Health Equity | 100.0 | 0 | Yes — Epidemiological Data Analysis |
| 5 | Gene Therapy × LADA | 100.0 | 0 | Partial — Literature Synthesis |

**Doctrine Alignment:** Gaps #3 (Islet Transplant × Drug Repurposing) and #1/#4 (Health Equity intersections) directly map to Tier 1 contribution areas. These remain high-priority candidates for computational contribution.

**Validation level:** BRONZE (single analytical source — per Research Doctrine, requires expert confirmation).

---

## Breaking News (Web Search — March 22-29, 2026)

### NEW since last report (March 28)

**Stanford T1D Remission Breakthrough — March 28, 2026**
Stanford researchers announced successful reversal of type 1 diabetes in 100% of mice through a double cell transplant (pancreatic islet cells + blood stem cells), creating a hybrid immune system that prevents destruction of insulin-producing cells — without immunosuppression drugs. Human clinical trials are planned. *Evidence level: 5 (preclinical — animal model only). Per Doctrine: "Demonstrated in animal model. Human relevance unconfirmed."*

**Aleniglipron Phase 2 Results (Structure Therapeutics) — March 16, 2026**
Oral small-molecule GLP-1 receptor agonist achieved 16.3% placebo-adjusted weight loss at 44 weeks with no plateau and only 3.7% discontinuation rate. Described as "injectable-like efficacy" in an oral formulation. FDA End-of-Phase 2 meeting scheduled Q2 2026; Phase 3 planned for H2 2026. *Evidence level: 1b (Phase 2 RCT). BRONZE validation.*

### Continuing from last report (still relevant)

**Awiqli (Insulin Icodec) — FDA APPROVED March 26, 2026**
First once-weekly basal insulin for T2D. Reduces injection burden from 7/week to 1/week. Novo Nordisk trial NCT07076199 tests further formulations and remains actively recruiting. *Evidence level: Regulatory action (G).*

**Wegovy HD (Semaglutide 7.2 mg) — FDA APPROVED March 19, 2026**
Higher-dose semaglutide for weight management. ~21% mean weight loss at 72 weeks. *Evidence level: Regulatory action (G).*

**Retatrutide Phase 3 Results (Eli Lilly) — March 19, 2026**
GLP-1/GIP/glucagon triple agonist: up to 2.0% A1C reduction and 16.8% weight loss. First-in-class Phase 3 data. *Evidence level: 1b (Phase 3 RCT). BRONZE validation (awaiting peer-reviewed publication).*

---

## Recommended Actions

### Immediate (Today)

1. **Re-run gap analysis — data is now at the 14-day stale threshold.**
   → `Run: python project1_literature_gap_analysis.py`

2. **Add Stanford T1D remission preclinical result to tracker** — New March 28 announcement. Record as Evidence Level 5 (preclinical). Note: 100% cure rate in mice but no human data yet. Monitor for planned clinical trial registration on ClinicalTrials.gov.

3. **Add aleniglipron Phase 2 data to tracker** — Structure Therapeutics oral GLP-1 with injectable-like efficacy. Phase 3 planned H2 2026. Record as BRONZE until peer-reviewed publication.

### This Week

4. **Review cross-domain paper PMID 41899527** — Systems-level transcriptomic integration linking T2D with drug repurposing networks. Aligns with Tier 1 Drug Repurposing Computational Screening.

5. **Review cross-domain paper PMID 41898821** — GDM genetics with epigenetics + multi-omics approach. Aligns with Tier 1 Multi-Omics Biomarker Integration.

6. **Update tracker with Awiqli approval** (if not already done from March 28 report) — FDA approved once-weekly insulin icodec. Significant T2D milestone.

7. **Update tracker with retatrutide Phase 3 data** (if not already done) — First-in-class triple agonist Phase 3 results.

### Ongoing Monitoring

8. **All automated scripts ran successfully** — hub_monitor.py, baseline_clinical_trials.py, and baseline_pubmed_alerts.py all produced fresh outputs on 2026-03-29. No script re-runs needed except gap analysis.

9. **Baricitinib Phase 3 trials** — NCT07222137 and NCT07222332 (Eli Lilly) remain actively recruiting. These are the first JAK inhibitor trials in T1D at Phase 3 — continue high-priority tracking.

10. **Watch for aleniglipron clinical trial registration** — Phase 3 planned H2 2026; a new ClinicalTrials.gov entry should appear in coming months.

---

*Report generated: 2026-03-29 | Next scheduled scan: 2026-03-30*
*Methodology: Research Doctrine v1.0 | Validation standards applied to all new claims*

Sources:
- [Stanford T1D Remission Breakthrough](https://nationaltoday.com/us/ca/stanford/news/2026/03/28/stanford-researchers-announce-breakthrough-in-type-1-diabetes-remission/)
- [Structure Therapeutics Aleniglipron Phase 2](https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access)
- [FDA Approves Awiqli](https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-awiqli-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes-302726839.html)
- [GLP-1 RA News March 2026](https://www.hcplive.com/view/diabetes-dialogue-glp-1-ra-news-updates-in-march-2026)
- [FDA Novel Drug Approvals 2026](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)
